S2Medical AB (publ)
STO:S2M
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.0085
0.1295
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one S2M stock under the Base Case scenario is 0.0322 SEK. Compared to the current market price of 0.0085 SEK, S2Medical AB (publ) is Undervalued by 74%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
S2Medical AB (publ)
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for S2M cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
S2Medical AB (publ)
Balance Sheet Decomposition
S2Medical AB (publ)
Current Assets | 5.1m |
Cash & Short-Term Investments | 1.4m |
Receivables | 1.7m |
Other Current Assets | 2m |
Non-Current Assets | 12.6m |
PP&E | 575k |
Intangibles | 12m |
Other Non-Current Assets | 1k |
Current Liabilities | 7.5m |
Accounts Payable | 1.1m |
Accrued Liabilities | 2.7m |
Other Current Liabilities | 3.8m |
Earnings Waterfall
S2Medical AB (publ)
Revenue
|
10.6m
SEK
|
Cost of Revenue
|
-1.1m
SEK
|
Gross Profit
|
9.5m
SEK
|
Operating Expenses
|
-7.3m
SEK
|
Operating Income
|
2.2m
SEK
|
Other Expenses
|
-4.1m
SEK
|
Net Income
|
-1.9m
SEK
|
Free Cash Flow Analysis
S2Medical AB (publ)
SEK | |
Free Cash Flow | SEK |
S2M Profitability Score
Profitability Due Diligence
S2Medical AB (publ)'s profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
S2Medical AB (publ)'s profitability score is 32/100. The higher the profitability score, the more profitable the company is.
S2M Solvency Score
Solvency Due Diligence
S2Medical AB (publ)'s solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
S2Medical AB (publ)'s solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
S2M Price Targets Summary
S2Medical AB (publ)
Dividends
Current shareholder yield for S2M is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
S2M Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
S2Medical AB engages in research and development in biotechnology. The company is headquartered in Linkoping, Ostergotland. The company went IPO on 2018-11-28. The firm focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The firm's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The firm is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
Officers
The intrinsic value of one S2M stock under the Base Case scenario is 0.0322 SEK.
Compared to the current market price of 0.0085 SEK, S2Medical AB (publ) is Undervalued by 74%.